NSHIFT
27.8.2021 12:10:11 CEST | Business Wire | Press release
nShift (www.nshift.com ), global provider of cloud delivery management solutions for e-commerce shops, retailers, manufacturers and 3PL companies, announces its launch.
With over 100+ pre-built third-party integrations into e-commerce and other shippers’ most critical IT systems and an unmatched carrier library delivering connectivity into over 700+ carriers, nShift offers customers an end-to-end cloud platform to automate and optimize the entire delivery management process – from label creation to delivery tracking and last mile logistics to returns management. nShift’s solutions have successfully enabled almost 1 billion annual shipments globally for e-commerce shops, retailers, manufacturers and 3PL companies. Through its extensive carrier library, nShift has unparalleled shipping visibility and reach, unlocking significant scalability for its customers – from 1 to millions of shipments annually – across the globe.
“I am extremely honored and excited to be joining nShift at such a pivotal time in its growth,” said Lars Pedersen, who was recently appointed CEO of nShift. “While our name is changing, we are more committed than ever to continuing to provide the vital connectivity in delivery management, visibility, and efficiency for which our 90,000+ customers rely on us. We are thrilled to announce our new brand together with our latest e-commerce innovations, nShift Checkout and nShift Return (formerly known as Returnado). Our platform enables customers to worry less and ship smarter with up to 10-20% higher e-commerce-shop conversions, 60% fewer delivery related support calls, and 30% increase in repurchase rates on returned products.”
Through the acquisition of Returnado, a Stockholm-based e-commerce returns management provider, nShift adds critical technology to its cloud delivery management platform with a streamlined return process for shippers, carriers, and recipients. Returnado’s returns expertise spans marquee brands such as Helly Hansen and Asket and demonstrates its significant capabilities to serve a very complicated portion of the logistics value chain.
Marlin Equity Partners and Francisco Partners, two of the world's leading technology investors, will remain the majority stakeholders in nShift.
Peter Chung, a Managing Director at Marlin Equity Partners, said, “We are excited to continue delivering against the nShift mission of enabling our customers to worry less and ship smarter via the Company’s collective scale and breadth of its consolidated, end-to-end cloud delivery management platform. Today, e-commerce and other shippers have a singular platform from which they can eliminate geographical barriers to growth and drive supply chain efficiency and visibility all while improving the overall delivery experience for constituents across the logistics value chain.”
Petri Oksanen, a Partner at Francisco Partners, added, “This is an exciting step forward and the beginning of the next chapter of transformational growth for nShift. With the recent acquisition and integration of Returnado, we are in a position now more than ever to continue to deliver the very best solutions for our customers and help them solve first-to-last mile logistics challenges, deliver tangible cost savings, and drive innovation in our industry.”
About nShift (www.nshift.com )
Established in 2021, nShift is the global leading provider of cloud delivery management solutions enabling the frictionless shipment and return of almost 1 billion shipments across 190 countries. nShift’s software is used globally by e-commerce, retail, manufacturing and 3PL shippers. The company is headquartered in London and Oslo. It has over 450 employees across offices in Sweden, Finland, Norway, Denmark, United Kingdom, Poland, the Netherlands, Belgium, Romania and Switzerland.
Stakeholders
About Marlin Equity Partners (www.marlinequity.com )
Marlin Equity Partners is a global investment firm with over $7 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries where its capital base, industry relationships and extensive network of operational resources significantly strengthen a company’s outlook and enhance value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 170 acquisitions. The firm is headquartered in Los Angeles, California with an additional office in London.
About Francisco Partners (www.franciscopartners.com )
Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 20 years ago, Francisco Partners has invested in more than 300 technology companies, making it one of the most active and longstanding investors in the technology industry. With more than $25 billion in assets under management, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential.
Companies Which Have Merged to Form nShift (note - all now rebranded as part of nShift with immediate effect)
About Returnado
Returnado is a Swedish e-commerce returns management platform launched in 2016. Returnado’s solutions optimize the “reverse e-commerce” returns process for retailers and consumers, and provides real-time analytics enabling customers to achieve 30%+ repurchase rates.
About Unifaun
Unifaun provides innovative delivery management solutions to carriers, shippers, and parcel recipients across the European transportation ecosystem. With an extensive partner ecosystem and carrier library, Unifaun enables customers to efficiently deliver almost 300 million shipments annually. Unifaun has over 200 employees across Sweden, Finland, Norway, Denmark, the Netherlands, Belgium, Germany, and Poland.
About Consignor
Consignor supports customers across the delivery processes by making it simpler, quicker, and cost-effective to ship orders to customers and by making delivery a competitive advantage. Consignor provides delivery management solutions, enabled through a wide-ranging carrier library, connecting shippers’ websites and warehouses with their customers. Consignor has more than 170 employees across offices in Oslo, Stockholm, Helsinki, Copenhagen, Aarhus, Bucharest, and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210827005148/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom